E-LIB Suche - Ergebnisse für: Barr, Paul M.

1

First‐line ibrutinib treatment in patients with chronic lym..:

Ghia, Paolo ; Owen, Carolyn ; Allan, John N....
HemaSphere. 8 (2024) 5 - p. , 2024

Link: https://doi.org/10.1002/..

2

Nivolumab plus brentuximab vedotin for relapsed/refractory ..:

Zinzani, Pier Luigi ; Salles, Gilles ; Moskowitz, Alison J....
Blood Advances. 8 (2024) 10 - p. 2400-2404 , 2024

Link: https://doi.org/10.1182/..

3

Response-adapted, time-limited venetoclax, umbralisib, and ..:

Hill, Brian T. ; Ma, Shuo ; Zent, Clive S....
Blood Advances. 8 (2024) 2 - p. 378-387 , 2024

Link: https://doi.org/10.1182/..

4

Integrative analysis of clinicopathological features define..:

Vose, Julie M. ; Fu, Kai ; Wang, Lu...
Journal of Hematology & Oncology. 16 (2023) 1 - p. , 2023

Link: https://doi.org/10.1186/..

5

ALK‐rearranged CD30‐positive poorly differentiated lung ade..:

George, Giby V ; Wallace, Danielle S ; Wang, Ying...
Histopathology. 84 (2023) 5 - p. 900-902 , 2023

Link: https://doi.org/10.1111/..

6

Rituximab induced cytokine release with high serum IP-10 (C..:

Moore, Jeremiah E. ; Bloom, Paige C. ; Chu, Charles C....
Leukemia Research. 129 (2023) - p. 107072 , 2023

Link: https://doi.org/10.1016/..

7

Outcomes in Patients with High-Risk Features after Fixed-Du..:

Allan, John N. ; Flinn, Ian W. ; Siddiqi, Tanya...
Clinical Cancer Research. 29 (2023) 14 - p. 2593-2601 , 2023

Link: https://doi.org/10.1158/..

8

Acalabrutinib and high-frequency low-dose subcutaneous ritu..:

Wallace, Danielle S. ; Zent, Clive S. ; Baran, Andrea M....
Blood Advances. 7 (2023) 11 - p. 2496-2503 , 2023

Link: https://doi.org/10.1182/..

9

Treatment Discontinuation Patterns for Patients With Chroni..:

Shadman, Mazyar ; Manzoor, Beenish S. ; Sail, Kavita...
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 7 - p. 515-526 , 2023

Link: https://doi.org/10.1016/..

10

Healthcare Utilization Disparities of Adolescent and Young ..:

Thapa, Kriti ; Strawderman, Myla ; Reagan, Patrick M....
Clinical Lymphoma Myeloma and Leukemia. 23 (2023) 9 - p. e260-e267 , 2023

Link: https://doi.org/10.1016/..

11

Outcomes of limited stage primary bone diffuse large B-cell..:

Rezazadeh, Alexandra ; Szabo, Aniko ; Khurana, Arushi...
Haematologica. , 2023

Link: https://doi.org/10.3324/..

12

A phase 1b study of ibrutinib in combination with obinutuzu..:

Ryan, Christine E. ; Brander, Danielle M. ; Barr, Paul M....
Leukemia. 37 (2023) 4 - p. 835-842 , 2023

Link: https://doi.org/10.1038/..

13

Nivolumab combined with brentuximab vedotin for R/R primary..:

Zinzani, Pier Luigi ; Santoro, Armando ; Gritti, Giuseppe...
Blood Advances. 7 (2023) 18 - p. 5272-5280 , 2023

Link: https://doi.org/10.1182/..

14

Characteristics and Clinical Outcomes of Patients with Chro..:

Woyach, Jennifer A. ; Barr, Paul M. ; Kipps, Thomas J....
Cancers. 15 (2023) 2 - p. 507 , 2023

Link: https://doi.org/10.3390/..

15

P617: FIXED-DURATION (FD) IBRUTINIB + VENETOCLAX FOR FIRST-..:

Ghia, Paolo ; Allan, John ; Siddiqi, Tanya...
HemaSphere. 7 (2023) S3 - p. e2822842 , 2023

Link: https://doi.org/10.1097/..